NanoEcho publishes investor letter

Read more about CEO Linda Persson and CTO Magnus Santesson as they tell more about their work to establish a strong company culture with a focus on delivery.

“It is essential that we ourselves are as driven as our staff, and that we maintain the same commitment that we want to see from them,” says Linda and Magnus.

You will also meet Professor and Chief Physician Henrik Thorlacius, senior medical advisor to NanoEcho, as he details how NanoEcho’s method may help rectal cancer patients in the future.

About NanoEcho

NanoEcho has developed a new technology for clearer diagnostics of, as the first phase, rectal cancer. The imaging technology is based on a new medical approach where nanotechnology is used in combination with modern ultrasound technology. The images that are generated are intended to facilitate differentiation between healthy and diseased tissue and at the same time determine the location of the cancer tissue more precisely. The aim is to provide more precise, simpler and less costly diagnosis of cancers and other diseases. With clearer diagnostics, the company wants to assist treating physicians with better guidance for more personalized treatment. Both the quality of life of the patients and their chance of survival can improve after treatment, with reduced treatment costs. www.nanoecho.se